SAGE Open Medicine (Oct 2022)

Emerging genetic biomarkers in lung adenocarcinoma

  • Jawad Barbar,
  • Maria Armach,
  • Mohammad Hassan Hodroj,
  • Sahar Assi,
  • Clara El Nakib,
  • Nathalie Chamseddine,
  • Hazem I Assi

DOI
https://doi.org/10.1177/20503121221132352
Journal volume & issue
Vol. 10

Abstract

Read online

Comprehensive genomic profiling is a next-generation sequencing approach used to detect several known and emerging genomic alterations. Many genomic variants detected by comprehensive genomic profiling have become recognized as significant cancer biomarkers, leading to the development of major clinical trials. Lung adenocarcinoma has become one of the most targeted cancers for genomic profiling with a series of actionable mutations such as EGFR, KRAS, HER2, BRAF, FGFR, MET, ALK, and many others. The importance of these mutations lies in establishing targeted therapies that significantly change the outcome in lung adenocarcinoma besides the prognostic value of some mutations. This review sheds light on the development of the comprehensive genomic profiling field, mainly lung adenocarcinoma, and discusses the role of a group of mutations in this disease.